Treatment for Diabetic Retinopathy

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Diabetic Retinopathy+9 More
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will help better define when someone with retinal vascular disease is progressing or regressing so that treatment can be more accurately given.

Eligible Conditions
  • Diabetic Retinopathy
  • Retinal Vascular Disorder
  • Hypertensive disease
  • Branch Vein Occlusion

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 5 years

5 years
Correlation of Imaging

Trial Safety

Safety Progress

1 of 3

Trial Design

0 Treatment Group

1050 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 5 years

Who is running the clinical trial?

National Eye Institute (NEI)NIH
515 Previous Clinical Trials
1,071,886 Total Patients Enrolled
45 Trials studying Diabetic Retinopathy
38,478 Patients Enrolled for Diabetic Retinopathy
Johns Hopkins UniversityLead Sponsor
2,055 Previous Clinical Trials
30,973,931 Total Patients Enrolled
5 Trials studying Diabetic Retinopathy
3,473 Patients Enrolled for Diabetic Retinopathy

Eligibility Criteria

Age 18+ · All Participants · 0 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 16th, 2021

Last Reviewed: October 24th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.